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Metformin is increasingly offered as an acceptable and economic alternative to insulin for
treatment of gestational diabetes mellitus (GDM) in many countries. However, the impact of
maternal metformin treatment on the trajectory of fetal, infant, and childhood growth is
unknown.
Methods and findings
PubMed, Ovid Embase, Medline, Web of Science, ClinicalTrials.gov, and the Cochrane
database were systematically searched (from database inception to 26 February 2019).
Outcomes of GDM-affected pregnancies randomised to treatment with metformin versus
insulin were included (randomised controlled trials and prospective randomised controlled
studies) from cohorts including European, American, Asian, Australian, and African women.
Studies including pregnant women with pre-existing diabetes or non-diabetic women were
excluded, as were trials comparing metformin treatment with oral glucose-lowering agents
other than insulin. Two reviewers independently assessed articles for eligibility and risk of
bias, and conflicts were resolved by a third reviewer. Outcome measures were parameters
of fetal, infant, and childhood growth, including weight, height, BMI, and body composition.
In total, 28 studies (n = 3,976 participants) met eligibility criteria and were included in the
meta-analysis. No studies reported fetal growth parameters; 19 studies (n = 3,723 neo-
nates) reported measures of neonatal growth. Neonates born to metformin-treated mothers
had lower birth weights (mean difference −107.7 g, 95% CI −182.3 to −32.7, I2 = 83%, p =
0.005) and lower ponderal indices (mean difference −0.13 kg/m3, 95% CI −0.26 to 0.00, I2 =
0%, p = 0.04) than neonates of insulin-treated mothers. The odds of macrosomia (odds ratio
[OR] 0.59, 95% CI 0.46 to 0.77, p < 0.001) and large for gestational age (OR 0.78, 95% CI
0.62 to 0.99, p = 0.04) were lower following maternal treatment with metformin compared to
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insulin. There was no difference in neonatal height or incidence of small for gestational age
between groups. Two studies (n = 411 infants) reported measures of infant growth (18–24
months of age). In contrast to the neonatal phase, metformin-exposed infants were signifi-
cantly heavier than those in the insulin-exposed group (mean difference 440 g, 95% CI 50 to
830, I2 = 4%, p = 0.03). Three studies (n = 520 children) reported mid-childhood growth
parameters (5–9 years). In mid-childhood, BMI was significantly higher (mean difference
0.78 kg/m2, 95% CI 0.23 to 1.33, I2 = 7%, p = 0.005) following metformin exposure than fol-
lowing insulin exposure, although the difference in absolute weights between the groups
was not significantly different (p = 0.09). Limited evidence (1 study with data treated as 2
cohorts) suggested that adiposity indices (abdominal [p = 0.02] and visceral [p = 0.03] fat
volumes) may be higher in children born to metformin-treated compared to insulin-treated
mothers. Study limitations include heterogeneity in metformin dosing, heterogeneity in diag-
nostic criteria for GDM, and the scarcity of reporting of childhood outcomes.
Conclusions
Following intrauterine exposure to metformin for treatment of maternal GDM, neonates are
significantly smaller than neonates whose mothers were treated with insulin during preg-
nancy. Despite lower average birth weight, metformin-exposed children appear to experi-
ence accelerated postnatal growth, resulting in heavier infants and higher BMI by mid-
childhood compared to children whose mothers were treated with insulin. Such patterns of
low birth weight and postnatal catch-up growth have been reported to be associated with
adverse long-term cardio-metabolic outcomes. This suggests a need for further studies
examining longitudinal perinatal and childhood outcomes following intrauterine metformin
exposure. This review protocol was registered with PROSPERO under registration number
CRD42018117503.
Author summary
Why was this study done?
• Gestational diabetes is a common pregnancy complication, affecting around 1 in 7 preg-
nancies worldwide, and can be associated with adverse outcomes for both mothers and
babies.
• There are several effective treatment strategies available for gestational diabetes, includ-
ing using metformin or insulin to control high blood sugars in the mother.
• It is important to fully understand any effects that these 2 treatment options may have
on the growth of the baby in the womb and also after birth into childhood.
What did the researchers do and find?
• We performed a systematic review of 28 studies that included 3,976 mothers who were
randomised to metformin or insulin for treatment of gestational diabetes. We included
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all studies that reported the weight and growth of their babies in the womb, at birth, or
later in childhood.
• We showed that babies whose mothers were treated with metformin weighed on average
108 g less at birth than those whose mothers were treated with insulin, and had a lower
risk of being born large (>90th centile) for their gestation at delivery.
• Metformin-exposed infants were 0.44 kg heavier by 18–24 months than insulin-exposed
infants. Metformin-exposed children had higher BMI (by 0.8 kg/m2) by mid-childhood
(5–9 years) than insulin-exposed children.
What do these findings mean?
• Metformin treatment for gestational diabetes alters the postnatal growth trajectory com-
pared to insulin treatment. Children exposed to metformin compared to insulin in the
womb tend to be born at significantly lower birth weights, but are heavier in infancy,
with higher BMI by mid-childhood.
• It is known that children who are born small and then undergo ‘catch-up growth’ after
birth are at increased risk of developing cardiovascular disease and type 2 diabetes later
in life. It is important to understand whether this increased risk applies to children
whose mothers were treated with metformin during pregnancy.
Introduction
Gestational diabetes mellitus (GDM) currently affects 3%–25% of pregnancies worldwide [1],
constituting a significant global healthcare burden. The continuing increase in the global inci-
dence of GDM may relate to new screening approaches, decreasing threshold values for diag-
nosis, or increases in population risk factors, particularly obesity [2,3]. GDM poses significant
risks to the immediate and long-term health of the mother and fetus. For the fetus, a key risk is
accelerated intrauterine growth, resulting in macrosomic or large for gestational age (LGA)
neonates [4,5]. At delivery, macrosomic and LGA neonates are at significantly elevated risk of
adverse perinatal outcomes, including shoulder dystocia, birth trauma, neonatal hypoglycae-
mia, and admission to neonatal intensive care [6,7]. Hence it is essential to implement effective
clinical interventions to maintain glycaemic control and limit fetal growth to within normal
parameters during GDM-affected pregnancies [8].
Insulin, the main endogenous hormone responsible for maintaining glucose homeostasis,
is an effective treatment for GDM [9]. However, the efficacy of insulin is weighed against sig-
nificant disadvantages. Insulin use can provoke maternal hypoglycaemia [10], increases the
tendency to maternal weight gain [11], requires injection, and is cumbersome to administer
and monitor [12,13]. In particular, the expense of insulin therapy and the difficulties with
refrigerated storage make it less suitable for use in low and middle development index settings,
where some of the greatest increases in incidence of GDM are currently observed [14]. There-
fore, the possibility of using oral glucose-lowering agents for treatment of GDM has been an
area of intense research interest [15–17].
Metformin (N,N-dimethylbiguanide), a biguanide oral glucose-lowering drug, has gained
widespread acceptance. Metformin is approved for use in the treatment of GDM in many
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countries across the world and is featured in the 20th World Health Organization (WHO)
essential medicines list [18], and it has been recommended by the Society for Maternal–Fetal
Medicine (SMFM) as a first line treatment for GDM [19]. Available evidence suggests that
metformin is effective in maintaining maternal glycaemic control and may help to limit gesta-
tional weight gain ([20] and reviewed in [21]). However, unlike insulin, metformin crosses the
placenta and is present at clinically relevant concentrations in fetal and placental tissues (50%–
100% of maternal concentrations) [22,23]. Thus, metformin exposure could potentially affect
the developing feto-placental unit via direct or indirect pathways other than control of mater-
nal hyperglycaemia.
A key aim of GDM treatment is to prevent fetal over-growth; consequently, several rando-
mised trials have examined the impact of metformin treatment on birth weight in GDM-
affected pregnancies [15–17,24–32]. However, there is no clear consensus on how fetal growth
is affected by metformin treatment, and whether intrauterine exposure to metformin has lon-
ger-term consequences for growth in infancy and childhood. The aim of our study was there-
fore to determine whether metformin compared to insulin treatment for GDM alters perinatal
growth trajectories or body composition from the time of fetal exposure through to mid-child-
hood. Addressing this issue is particularly important as the number of pregnancies exposed to
metformin increases worldwide [8].
Methods
This systematic review and meta-analysis was conducted in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [33]. The
PRISMA checklist is detailed in S1 PRISMA Checklist. The systematic review protocol was
registered in PROSPERO (CRD42018117503) (S1 Text). Ethical approval was not required.
Literature searches, search strategies, and eligibility criteria
Systematic literature searches using pre-specified terms (S2 Text) were performed on PubMed
(June 1997 to 26 February 2019), Ovid Embase (1974 to 26 February 2019), Ovid Medline
(1946 to 26 February 2019), Cochrane Library (database inception to 26 February 2019), Clini-
calTrials.gov (database inception to 26 February 2019), and Web of Science (1900 to 26 Febru-
ary 2019). No filters were applied to any of the searches. No language or location restrictions
were applied.
Studies that randomised women with GDM to metformin versus insulin therapy were
included. Studies were excluded if they compared metformin to other oral glucose-lowering
agents (e.g., glyburide) or if interventions were given prior to pregnancy. GDM was screened
for and diagnosed according to local criteria in each study, and we did not apply exclusions
with respect to this. Studies were excluded if they included participants with multiple pregnan-
cies or pre-existing diabetes, or if they randomised fewer than 50 women in total. Studies were
excluded if trial participants were omitted from the study on the basis of fetal weight and/or
birth weight. Data reported only in meeting abstracts would have been included if the abstract
contained sufficient information for assessment, but none met this standard. Where the avail-
able information for assessment was insufficient, authors were contacted for further informa-
tion. Two out of the 8 authors contacted for further information responded to this request.
One author reported the use of permuted block randomisation in their study [34], and the
other stated that a random allocation of treatments was used, yet did not specify what the
nature of the randomisation was, and that study assessors were blinded to the treatment
groups [25].
Post-natal growth following maternal treatment for GDM
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Study selection and data extraction
Two reviewers (JLT-A and CEA) independently assessed each study using predetermined
inclusion/exclusion criteria (detailed in S1 Table). A third reviewer (SEO) was available to
resolve cases where eligibility was unclear. An initial screen of titles and abstracts was per-
formed, followed by a detailed full paper screen. The results from each step of the review pro-
cess are documented in a PRISMA flow diagram (Fig 1).
Fig 1. PRISMA flow diagram.
https://doi.org/10.1371/journal.pmed.1002848.g001
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Data extraction from eligible studies was conducted independently by 2 authors (JLT-A
and CEA). Outcome measures were fetal growth parameters (head circumference, abdominal
circumference, femur length, biparietal diameter, and estimated fetal weight calculated by any
formula; millimetres or grams); birth weight (grams or kilograms); small for gestational age
(SGA) (birth weight < 10th centile for gestational age; n and percent); LGA (birth
weight > 90th centile for gestational age; n and percent); macrosomia (birth weight > 4 kg; n
and percent); neonatal, infant, and child heights (centimetres); neonatal ponderal index (kg/
m3); BMI (kg/m2); abdominal, head, chest, and waist circumferences (centimetres); skinfold
thicknesses (bicep, tricep, and subscapular; millimetres); fat masses (arm, abdominal, thigh,
and total; grams); and fat volumes (abdominal, visceral, and abdominal subcutaneous; cm3).
Where multiple time points were reported for the same population, we included data from
each time point, provided it fell within 1 of the 4 specified study time frames: (i) third trimester
of pregnancy (28–40 weeks), (ii) neonatal period (at birth or within 6 weeks), (iii) infancy (18
months–2 years), or (iv) mid-childhood (5–9 years).
Quality assessment of included studies (risk of bias in individual studies)
Each study was independently assessed by 2 authors (JLT-A and CEA) for quality and validity
using the Cochrane Collaboration tool for assessing risk of bias. Seven risk-of-bias domains
were assessed for each study, and each domain was given a rating of low risk, unknown risk, or
high risk of bias (S2 Table). All risk-of-bias analysis was conducted at the study level.
The principle summary measures utilised in this systematic review were unadjusted odds
ratios (ORs) (for dichotomous data) or differences in means (for continuous data). Meta-anal-
ysis was performed using Review Manager (RevMan) version 5.3 (Nordic Cochrane Centre,
Copenhagen, 2014) and the ‘metafor’ package in R version 3.5.1 [35]. Funnel plots were con-
structed to assess publication bias, and outcome measures with 5 or more studies included
were also subjected to Egger’s test. Heterogeneity between studies was assessed using the I2 sta-
tistic, and any outcomes showing significant inter-study heterogeneity were analysed using a
random-effects model. Sensitivity analyses were performed using leave-one-out testing for
individual studies and for studies grouped according to GDM criteria [35], and by conducting
meta-analyses using only the subset of studies assessed as being high quality (i.e., low risk of




Electronic searching of the specified databases yielded a total of 2,559 studies, and 1 further
study was found via hand-searching. After removal of duplicates and title/abstract screening,
121 trials received full text assessment, applying the full set of eligibility criteria (Fig 1). After
full text evaluation, a total of 28 studies remained eligible for inclusion, representing 3,976
pregnancies (Fig 1).
The included studies varied in terms of quality and design (S3 Table). Outcomes measured
varied between studies, with birth weight the most commonly reported outcome (17 studies).
There was considerable clinical heterogeneity in the dose of metformin used (ranging from
500 mg to 3,000 mg daily) both within and between studies. There was also heterogeneity
between studies in criteria used to diagnose GDM, with a total of 8 different diagnostic criteria
used, including those specified by the American College of Obstetricians and Gynecologists,
American Diabetes Association, Australasian Diabetes in Pregnancy Society, Carpenter–Cou-
stan, Finnish national criteria, International Association of Diabetes and Pregnancy Study
Post-natal growth following maternal treatment for GDM
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002848 August 6, 2019 6 / 20
Groups, National Diabetes Data Group, and WHO (S3 Table). We therefore performed a
leave-one-criterion-out sensitivity analysis for birth weight (the primary and best-evidenced
finding of this meta-analysis) to demonstrate that use of different thresholds for GDM diagno-
sis did not have a significant impact on the result (S1 Fig). There was also a range of geographi-
cal settings including Europe [15,17,36–38], US [39], Australia/New Zealand [16,40,41], South
Asia [31,42] and Africa and the Middle East [24–30,34,43–46].
The risk of bias was low in the majority of included studies. However, 6 studies did not ana-
lyse data on an intention-to-treat basis (i.e., trial participants who did not achieve adequate
glycaemic control with metformin were removed from the study [24–26,28,30,34], leading to
an overall high risk of bias). A further study had significant imbalance in the baseline charac-
teristics of participants, potentially due to failure of randomisation [42]. We performed sub-
group meta-analyses excluding the studies assessed as having an overall high risk of bias (low-
quality studies). Subgroup analysis of only high-quality studies showed that removal of the
low-quality studies did not materially alter the outcome of the meta-analysis for any of the out-
comes assessed; therefore, all studies were included (S2 Fig). We also assessed the likelihood of
single studies significantly influencing the overall results using leave-one-out analysis. We
demonstrated that the results of the meta-analyses of birth weight, macrosomia, and SGA were
robust to the omission of single studies. The summary effect size for the outcome of LGA was
non-significant when various studies were removed, decreasing our confidence in the robust-
ness of this finding (S3 Fig). Funnel plots for all outcomes were assessed visually (S4 Fig).
There were no obvious asymmetries in the plots for any study outcomes, with the exception of
macrosomia in studies judged to be high quality. Egger’s test (p< 0.05) confirmed the likeli-
hood of publication bias with respect to macrosomia in these studies, but not with respect to
all included studies. Visual inspection of the funnel plots confirmed that there was no reason
to believe that significant publication bias affected any of the other outcomes studied.
Fetal growth and neonatal outcomes
No eligible studies reported fetal growth outcomes in metformin- versus insulin-treated GDM
pregnancies.
Nineteen studies (n = 3,723 neonates) reported neonatal growth parameters. Birth weights
of neonates born to mothers treated with metformin were significantly lower than those of
neonates whose mothers were treated with insulin during pregnancy. On average, metformin-
exposed neonates were 107.7 g smaller than those whose mothers were randomised to insulin
(95% CI 32.7 to 182.3, I2 = 83%, p = 0.005) (Fig 2). In keeping with the overall lower birth
weight in the metformin-exposed group, macrosomia was lower by 40% compared to the insu-
lin-exposed group (OR 0.59, 95% CI 0.46 to 0.77, I2 = 0%, p< 0.001), although this result may
be influenced by publication bias (Fig 3). LGA was also lower in metformin-exposed neonates
compared to insulin-exposed neonates (OR 0.78, 95% CI 0.62 to 0.99, I2 = 7%, p = 0.04) (Fig
4). However, the difference in LGA between metformin- and insulin-exposed neonates was no
longer significant when leave-one-out analysis was performed (S3 Fig). There was no differ-
ence in the risk of being born SGA (OR 0.99, 95% CI 0.68 to 1.46, I2 = 0%) (Fig 5) or in neona-
tal height (mean height difference 0.03 cm, 95% CI −0.71 to 0.77, I2 = 78%) between the
treatment groups (Fig 6).
Three studies reported neonatal ponderal index [15,16,29] (n = 986 neonates). Neonatal
ponderal index was significantly lower in the metformin-exposed compared with the insulin-
exposed group (−0.13, 95% CI −0.26 to −0.00; I2 = 0%, p = 0.04) (Fig 7). Only 1 study [16] (n =
733 neonates) reported neonatal abdominal circumference, which was not significantly differ-
ent between groups (Fig 8). However, 3 studies reported neonatal head circumference
Post-natal growth following maternal treatment for GDM
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[15,16,29] (n = 986 neonates), which was significantly lower in the metformin-exposed group
(−0.21 cm, 95% CI −0.39 to −0.03, I2 = 53%, p = 0.02) (Fig 9) compared to the insulin-exposed
group, as was chest circumference, which was reported in 2 studies [16,29] (n = 893 neonates)
(−0.34 cm, 95% CI −0.62 to −0.05, I2 = 42%, p = 0.02) (Fig 10).
Infant growth (18 months–2 years) and childhood growth (5–9 years)
Two studies [16,36] (n = 411 infants) reported weight during infancy (between 18 months and
2 years of age). Infants of mothers treated with metformin during pregnancy were significantly
heavier than infants of mothers treated with insulin during pregnancy (mean difference 440 g,
Fig 2. Birth weight. Expressed as mean difference (random effects model). IV, mean difference.
https://doi.org/10.1371/journal.pmed.1002848.g002
Fig 3. Macrosomia. Expressed as OR (fixed effects model) and 95% CI. M-H, odds ratio; met., metformin.
https://doi.org/10.1371/journal.pmed.1002848.g003
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95% CI 50 to 830, I2 = 4%, p = 0.03) (Fig 11). However, infant height was not significantly dif-
ferent between treatment groups (0.65 cm, 95% CI −1.31 to 2.61, I2 = 80%) (Fig 12).
Two studies [38,41] reported weight during mid-childhood (n = 301 children). One of
these studies [41], reported outcomes from 2 different sites. Children of mothers treated with
metformin during pregnancy tended to be heavier than children of mothers treated with insu-
lin during pregnancy, but this difference did not reach statistical significance (mean difference
1.13 kg, 95% CI −0.19 to 2.45, I2 = 20%, p = 0.09) (Fig 13). However, childhood BMI, reported
in 2 studies [38,41] (n = 301 children), was significantly higher in the metformin-exposed
group than in the insulin-exposed group (mean difference 0.78 kg/m2, 95% CI 0.23 to 1.33, I2
= 7%, p = 0.005) (Fig 14). As with height at birth and in infancy, there was no difference in
height in childhood between the treatment groups (Fig 15). A follow-up study (n = 208 chil-
dren) [41] from different sites of a single randomised controlled trial [16] examined anthro-
pometry and body composition in mid-childhood. None of the measured growth parameters
(head, chest, and waist circumference, and weight:height ratio) was significantly different
between the 2 treatment groups (S5 Fig). However, this study demonstrated [41] higher
Fig 4. Large for gestational age. Expressed as OR (fixed effects model) and 95% CI. M-H, odds ratio; met., metformin.
https://doi.org/10.1371/journal.pmed.1002848.g004
Fig 5. Small for gestational age. Expressed as OR (fixed effects model) and 95% CI. M-H, odds ratio; met., metformin.
https://doi.org/10.1371/journal.pmed.1002848.g005
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abdominal (p = 0.02) and visceral (p = 0.03) fat volumes in metformin-exposed children com-
pared to the children whose mothers were treated with insulin during pregnancy (Table 1).
There were no significant differences between the groups in terms of total fat mass or abdomi-
nal fat mass assessed by dual X-ray absorptiometry scanning in mid-childhood (Table 1).
Discussion
In this study of randomised evidence, we found that neonates exposed to metformin in utero
weighed less at birth than neonates whose mothers were exposed to insulin, in the context of
treatment for GDM. The risk of macrosomia is substantially lower, by 40%, when GDM is
treated with metformin compared to insulin, without a concomitant increase in the risk of
being born SGA. The limited number of studies that have addressed neonatal anthropometry
suggest that metformin-exposed neonates have lower lean mass compared to neonates whose
mothers were treated with insulin, in terms of lower ponderal index, head circumference, and
chest circumference with no change in abdominal circumference.
Despite being born at lower average birth weights, by the age of 2 years, metformin-exposed
infants were heavier than infants whose mothers were treated with insulin [36,40]. In mid-
childhood (5–9 years), the absolute weight difference between groups did not reach statistical
significance [38,40], but children exposed to metformin in utero had higher BMI (by 0.78 kg/
m2) than those whose mothers were treated with insulin [38,40]. Very limited data were avail-
able on body composition in infancy or childhood, but those available showed no significant
differences on any specific anthropometric parameters [41]. Follow-up studies (from 2 differ-
ent sites) based on a single original trial [16] also included detailed assessments of adiposity in
childhood [41]. These suggested that the higher BMI observed in children exposed to metfor-
min in utero compared to those exposed to insulin may be the result of greater abdominal adi-
posity (as evidenced by higher visceral and abdominal fat volumes), which is known to be
strongly associated with cardio-metabolic disease in later life [47].
Fig 6. Neonatal height. Expressed as mean difference (random effects model) and 95% CI. IV, mean difference.
https://doi.org/10.1371/journal.pmed.1002848.g006
Fig 7. Neonatal ponderal index. Expressed as mean difference (fixed effects model) and 95% CI. IV, mean difference.
https://doi.org/10.1371/journal.pmed.1002848.g007
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Strengths
A major strength of our meta-analysis is our ability to provide a complete overview of the
effect of intrauterine metformin exposure on perinatal growth and body composition via serial
meta-analyses in discrete developmental windows [48–55]. Our study design maximally lever-
ages available data to provide the most complete possible analysis of growth patterns from
intrauterine development to mid-childhood using available data. Our findings highlight the
lack of published serial fetal growth data from any randomised trial that met the inclusion cri-
teria for this study.
Previous studies have examined various outcomes of intrauterine metformin exposure in
mixed populations with a variety of indications [56]. A further strength of our study was that
in order to standardise expected growth trajectories as far as possible, we limited our analysis
to studies of women with confirmed GDM. GDM is associated with accelerated fetal growth
trajectories [57], and thus any impact of metformin exposure on perinatal growth trajectories
is likely to be magnified and more readily detectable in GDM-affected populations. Moreover,
GDM is the most common clinical indication for use of metformin during pregnancy, which
is endorsed in many national guidelines, including in the UK [58,59] and New Zealand [60],
and by societies including the International Federation of Gynecology and Obstetrics [61] and
SMFM [19], making our study findings more directly applicable to clinical practice.
A further strength of our meta-analysis is that our findings appear robust across different
global populations, including both high and low-middle development index settings. Further-
more, other large well-conducted studies in which women were randomised to metformin
treatment during pregnancy for other indications reinforce our finding of altered postnatal
body composition following in utero metformin exposure. Vanky and colleagues studied chil-
dren of women treated with metformin for polycystic ovary syndrome. Their study [62]
included 160 children from 2 sites in Norway who were followed up at the age of 4 years. They
showed that those who were exposed to metformin in utero had increased weight z-score (dif-
ference in means 0.38, 95% CI 0.07 to 0.69), increased risk of overweight/obesity (OR 2.17,
95% CI 1.04 to 4.61), and increased BMI (difference in means 0.45 kg/m2, 95% CI 0.11 to 0.78)
Fig 8. Neonatal abdominal circumference. Expressed as mean difference (fixed effects model) and 95% CI. IV, mean difference.
https://doi.org/10.1371/journal.pmed.1002848.g008
Fig 9. Neonatal head circumference. Expressed as mean difference (fixed effects model) and 95% CI. IV, mean difference.
https://doi.org/10.1371/journal.pmed.1002848.g009
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compared to those who were exposed to placebo in utero. When these children (n = 144) were
followed up at 5–10 years of age [63], children whose mothers were treated with metformin
maintained the increased BMI observed at 4 years of age (difference in means 0.41 kg/m2, 95%
CI 0.03 to 0.78). Moreover, data from a randomised trial of 449 overweight or obese normogly-
caemic women randomised to metformin or placebo from 16 weeks of gestation (EMPOWaR),
showed that neonates exposed to metformin compared to placebo in utero were thinner at
birth (lower neonatal ponderal index), suggesting very early differences in body composition
[64,65]. Our confidence in our finding of a higher tendency towards lower lean mass and
greater adiposity in metformin-exposed compared to insulin-exposed children is increased by
these studies.
Limitations
The ability to draw definitive conclusions from our meta-analysis is limited by both the quan-
tity and quality of the studies available. In particular, longitudinal follow-up data into mid-
childhood from trials of GDM treatment are sparse in comparison to earlier time points (110–
301 children from 3 studies). Where follow-up data are available, the original studies may be
subject to recall bias and power issues with respect to childhood outcomes. The majority of
clinical trials in this area are powered only for primary outcomes at the time of birth. Our find-
ings highlight a need for further longitudinal studies of growth and body composition follow-
ing intrauterine metformin exposure.
The overall lower incidence of macrosomia and the average lower birth weight associated
with metformin compared to insulin treatment in trial contexts has been interpreted as evi-
dence of efficacy and beneficial impact on fetal growth. However, our meta-analysis demon-
strates a lack of data on which to base conclusions regarding fetal growth trajectories and
neonatal body compositions associated with lower birth weight. In the absence of such data, it
is challenging to determine whether lower birth weight represents lower lean mass (as possibly
indicated by a lower ponderal index) or lower fetal adiposity (in keeping with maintenance of
normoglycaemia in GDM). This uncertainty underlines the necessity for studies examining
Fig 10. Neonatal chest circumference. Expressed as mean difference (fixed effects model) and 95% CI. IV, mean difference.
https://doi.org/10.1371/journal.pmed.1002848.g010
Fig 11. Infant weight. Expressed as mean differences (fixed effects model) and 95% CI. IV, mean difference.
https://doi.org/10.1371/journal.pmed.1002848.g011
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the consequences of intrauterine metformin exposure for fetal growth and postnatal catch-up
growth, which is associated with cardiovascular and metabolic disease risk in later life [48–55].
Regarding study quality, there was considerable risk of bias associated with a number of
studies, particularly with regard to poorly described or quasi-randomisation procedures [24–
26,31,42,44,45]. In all trials, women who were randomised to, but not successfully treated
with, metformin (defined as failure to maintain plasma glucose within the defined range) were
subsequently offered insulin treatment. Several trials then excluded women who required both
metformin and insulin treatment from the final analyses [24–26,28,30,34], rather than con-
tinuing to analyse their data on an intention-to-treat basis. Women who were not adequately
treated with metformin ranged from 14% to 46% of the total randomised to metformin.
Hence, the exclusion of these women may represent the introduction of serious bias into the
trial results. In particular, the women who were not successfully treated with metformin alone
may have had more adverse outcomes overall, and so their exclusion may skew the effect esti-
mates compared to studies where intention-to-treat analysis was performed. In order to assess
whether bias introduced through this route impacted the meta-analysis results overall, we con-
ducted a sensitivity analysis excluding studies in which analysis was not performed on an
intention-to-treat basis. As exclusion of these studies did not substantively alter the results of
any reported outcome, we have included studies that were not analysed on an intention-to-
treat basis in our study. An additional limitation is the inter-study heterogeneity in the diag-
nostic criteria used for GDM, reflecting the geographical and date spread of the included stud-
ies. In total, 8 different diagnostic criteria were used. Furthermore, in some studies the
diagnostic criteria were changed during recruitment [17,37,38,66]. Diagnosing GDM at lower
glucose intolerance thresholds may decrease the effect size of the observed response to treat-
ment. However, our sensitivity analysis with respect to diagnostic criteria indicates that this
did not materially alter the overall conclusions.
Interpretation
We show that metformin-exposed babies are born smaller than their insulin-exposed counter-
parts, with lower ponderal index, but then undergo accelerated postnatal growth such that by
Fig 12. Infant height. Expressed as mean differences (random effects model) and 95% CI. IV, mean difference.
https://doi.org/10.1371/journal.pmed.1002848.g012
Fig 13. Childhood weight. Expressed as mean differences (fixed effects model) and 95% CI. IV, mean difference.
https://doi.org/10.1371/journal.pmed.1002848.g013
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infancy they have higher weight and by childhood they have higher BMI. This is a concerning
finding, as previous evidence from a variety of contexts suggests that such patterns of low birth
weight and postnatal catch-up growth can be associated with adverse long-term cardio-meta-
bolic outcomes [48–55].
Metformin readily crosses the placenta via organic cation transporters and may reach con-
centrations in the fetus approaching those in the mother [22,23]. Organic cation transporters
are present in both placental and fetal tissues in the second and third trimester, which is the
period during which treatment for GDM takes place [67]. Metformin has a variety of intracel-
lular effects, including inhibition of mitochondrial respiration [68] and effects on the mTOR
pathway, by both AMPK-dependent [69] and AMPK-independent [70] mechanisms. mTOR
is important for nutrient sensing, and it is known that metformin can act upon mTOR and
cause nutrient restriction of glucose and amino acids to the fetus and placenta [71]. The
growth pattern seen in infants exposed to metformin compared to insulin for treatment of
GDM (low birth weight followed by accelerated post-natal catch-up growth) closely resembles
that of the nutritionally deprived fetus. Such growth patterns have been reported in several
studies to be associated with adverse cardio-metabolic consequences in later life including obe-
sity, type 2 diabetes, and cardiovascular disease [48–55]. Data on the very long-term conse-
quences of fetal metformin exposure are currently lacking, as are data on intrauterine growth
trajectories, detailed perinatal phenotyping, and placental effects of metformin exposure.
These are important future research priorities. The impact of other oral glucose-lowering
agents used in GDM treatment, for example glyburide, which is used in certain countries such
as the US [9], was not addressed in the current analysis. The impact of such treatment on fetal,
infant, and long-term growth is therefore another important research priority.
Our observations are timely because the incidence of GDM is increasing rapidly in many
populations, with 1 in 7 of all babies being born to GDM-affected mothers in 2017 globally
[72]. Importantly, the incidence of GDM is also rising in populations in which treating GDM
with insulin is unlikely to be feasible for large numbers of women [73]. Treating GDM with
metformin is becoming more common and is being introduced into a growing number of
Fig 14. Childhood BMI. Expressed as mean differences (fixed effects model) and 95% CI. IV, mean difference.
https://doi.org/10.1371/journal.pmed.1002848.g014
Fig 15. Childhood height. Expressed as mean differences (fixed effects model) and 95% CI. IV, mean difference.
https://doi.org/10.1371/journal.pmed.1002848.g015
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countries (reviewed in [74]); thus, it is a research priority to ensure that such treatment is not
detrimental to long-term health [75].
It has been demonstrated in many studies that the patterns of growth in in utero and early
postnatal periods are associated with long-term metabolic consequences, including obesity,
cardiovascular disease, and impaired glucose tolerance [48–55,76,77]. The current findings
demonstrate that metformin treatment of GDM alters the postnatal growth trajectory com-
pared to insulin treatment. Children exposed to metformin compared to insulin in utero were
born at significantly lower birth weights, but were significantly heavier in infancy, with higher
BMI by mid-childhood. These data warrant further detailed investigation of the implications





S1 Fig. Leave-one-criterion-out sensitivity analysis for birth weight. (A) Minus American
Diabetes Association (ADA), (B) minus Australasian Diabetes in Pregnancy Society (ADIPS),
(C) minus American College of Obstetricians and Gynecologists (ACOG), (D) minus Carpen-
ter–Coustan (CC), (E) minus Finnish national criteria, (F) minus International Association of
Diabetes and Pregnancy Study Groups (IADPSG), (G) minus National Diabetes Data Group
(NDDG) (H) minus World Health Organization (WHO), and (I) minus studies without GDM
criteria details.
(PPTX)
Table 1. Childhood adiposity indices.
Adiposity index Study details Mean difference (fixed) 95% CI Significance Heterogeneity test
Total fat mass (DEXA) Adelaide (n = 61)
Auckland (n = 98)
0.20 −0.11, 0.51 p = 0.25 p = 0.15, I2 = 52%
Abdominal fat mass (DEXA) Adelaide (n = 61)
Auckland (n = 98)
79.80 −59.32, 218.92 p = 0.26 p = 0.11, I2 = 60%
Abdominal fat volume (MRI) Adelaide (n = 12)
Auckland (n = 92)
0.44 0.06, 0.82 p = 0.02 p = 0.84, I2 = 0%
Abdominal subcutaneous fat volume (MRI) Adelaide (n = 12)
Auckland (n = 92)
0.29 −0.07, 0.65 p = 0.11 p = 0.95, I2 = 0%
Visceral fat volume (MRI) Adelaide (n = 12)
Auckland (n = 92)
0.41 0.05, 0.77 p = 0.03 p = 0.85, I2 = 0%
Thigh fat mass (DEXA) Adelaide (n = 61)
Auckland (n = 98)
90.77 −148.68, 330.23 p = 0.46 p = 0.46, I2 = 61%
Arm fat mass (DEXA) Adelaide (n = 61)
Auckland (n = 98)
102.57 −73.34, 278.47 p = 0.25 p = 0.09, I2 = 65%
Bicep skinfold thickness Adelaide (n = 109)
Auckland (n = 98)
0.53 −0.60, 1.66 p = 0.35 p = 0.21, I2 = 36%
Tricep skinfold thickness Adelaide (n = 109)
Auckland (n = 98)
0.64 −0.76, 2.04 p = 0.83 p = 0.37, I2 = 70%
Subscapular skinfold thickness Adelaide (n = 109)
Auckland (n = 98)
1.05 −0.70, 2.79 p = 0.24 p = 0.32, I2 = 0%
All outcomes expressed as mean difference, with the exception of abdominal, abdominal subcutaneous, and visceral fat volumes, which are expressed as standard mean
difference. All outcomes used fixed model effects and 95% CI. Significant p-values are in bold. Units: fat mass, grams; fat volume, cm3; skinfold thickness, millimetres.
All data from Rowan et al. [41]. DEXA, dual X-ray absorptiometry.
https://doi.org/10.1371/journal.pmed.1002848.t001
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S2 Fig. Subgroup analysis exploring whether removal of biased studies affects outcomes.
(A) Birth weight, (B) macrosomia, (C) LGA, and (D) SGA. All outcomes expressed as OR
(95% CI), with the exception of birth weight, which is expressed as mean difference (95% CI).
(PPTX)
S3 Fig. Leave-one-out sensitivity analysis. (A) Birth weight, (B) macrosomia, (C) LGA, and
(D) SGA. All outcomes expressed as OR (95% CI).
(PPTX)
S4 Fig. Funnel plots to assess publication bias. All outcomes plotted.
(PPTX)
S5 Fig. Childhood (7–9 years) anthropometry. (A) Childhood head circumference, (B) child-
hood chest circumference, (C) childhood waist circumference, and (D) childhood waist:hip
ratio. All outcomes expressed as mean differences (95% CI).
(PPTX)
S1 Table. Inclusion/exclusion criteria.
(PPTX)
S2 Table. Risk-of-bias assessment. (A) Random sequence generation (selection bias), (B) allo-
cation concealment (selection bias), (C) blinding participants and personnel (performance
bias), (D) blinding of outcome assessment (detection bias), (E) incomplete oucome data (attri-
tion bias), (F) selection bias (reporting bias), and (G) other bias.
(PPTX)
S3 Table. Study characteristics.
(XLSX)
S1 Text. PROSPERO protocol. CRD42018117503.
(PPTX)
S2 Text. Database search strategies. (A) PubMed, (B) Ovid Embase, (C) Medline, (D) Web of
Science, (E) Cochrane Library, and (F) ClinTrials.gov.
(PPTX)
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